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Abstract
Ischemic Mitral Regurgitation (MR) affects a large portion of patients suffering from ischemic
heart disease. Significant MR develops in one quarter to one third of patients who suffer from
ischemic heart disease and doubles their late mortality rate after a myocardial infarction or
revascularization. MR is most often caused by the bulging, or remodeling, of the heart's left
ventricle. This remodeling displaces the papillary muscles inside of the ventricle and tethers the
mitral valve, preventing it from closing properly. Current treatments attempt to either repair or
replace the valve. These treatments require the heart be stopped and the patient be placed on a
cardiopulmonary bypass pump for many hours. Both treatment approaches have serious side-
effects, including relapse of the MR as quickly as six months post-operatively.
This thesis concerns the development of an active artificial muscle patch (AMP) for application
to the exterior of the heart. The AMP constructively remodels the heart in order to alleviate MR.
Two in-vivo experiments were conducted with a heart-gated fluid pumping apparatus connected
to a balloon patch that successfully proofed the concept that an active patch can relieve MR.
These experiments also established data on the mechanical requirements of such a patch. An in-
vitro heart model was created to test iterations of AMP devices before undergoing further in-vivo
studies. Development of an AMP using Nickel-Titanium shape memory alloy was begun and
iterations of this device have had early success in in-vitro tests.
Thesis Supervisor: Ian W. Hunter
Title: Hatsopoulos Professor of Mechanical Engineering and Professor of Biological Engineering
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I Introduction
1.1 Addressing Problems of Heart Disease: The Case of Ischemic
Mitral Regurgitation
Ischemic mitral regurgitation (MR) is a common complication of ischemic heart disease.
A patient suffering from ischemic heart disease will often develop a region of weakened tissue
where the heart is deprived of oxygen. This weakened area tends to bulge outwards under normal
bio-mechanical stress. When this bulging area is located on the left ventricle (LV), the papillary
muscles (PM) on the LV's endocardium are displaced and will often tether the leaflets of the
mitral valve, preventing them from coapting and causing regurgitation back into the left atrium
(LA)[1]. The physiology of the mitral valve is shown in Figure 1. This process of LV remodeling
can lead to serious complications. Significant MR develops in one quarter to one third of patients
who suffer from ischemic heart disease and doubles their late mortality rate after a myocardial
infarction or revascularization[2,3,4].
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Figure 1: The mitral valve.
Figure 2 shows an image taken with an echocardiograph of a sheep suffering from MR.2
The echocardiograph assigns colors to blood flow vectors. In Figure 2, the red color indicates a
flow towards the echo probe while a blue color indicates a flow away from the probe. This
makes it very easy to visualize any backflow through the mitral valve. The tenting of the valve's
leaflets caused by PM displacement can also be seen.
Illustration source: [5].
2 Echocardiography is the staple observation technique for MR.
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Lateral papillary Medial papillary
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Figure 2: Echocardiograph of MR in a sheep's heart[1].
1.2 Current Approaches to Treatment
Approximately 18,000 patients have mitral valve surgery per year[5]. The current
treatments for MR are mitral ring annuloplasty or mitral valve replacement. Mitral ring
annuloplasty involves installing an oval plastic ring around the mitral annulus.3 This plastic ring
has an outer diameter slightly smaller than that of the valve. By suturing the annulus to this ring,
the annulus is reduced in size, bringing the valve's leaflets closer together which allows them to
coapt and prevent further MR. The problem with this treatment is two-fold. First, any valve
surgery is both major and relatively high risk. During surgery, the heart must be stopped and the
patient must be placed on a cardiopulmonary bypass pump 4 for several hours (average valve
3 Mitral valve's base.
4 Referred to as being placed "on-pump." The cardiopulmonary bypass pump oxygenates the blood and provides
blood flow throughout the body to keep the body alive while the operation is on-going.
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repair surgery duration is four hours)[6]. Most importantly however, MR often recurs within a
year if LV remodeling persists[7,8,9,10].
Mitral valve replacement involves replacing the entire valve with a mechanical or xeno-
biological 5 substitute. To treat ischemic MR, a mechanical valve is generally used since the new
valve can function independently of any remodeling of the LV. Major drawbacks of this
procedure are that it also requires the patient to be placed on a cardiopulmonary bypass pump
during the surgery. There are also long-term drawbacks such as the patient needing to take anti-
coagulant medication for life to prevent blood clots forming in and around the new valve[1 1].
Both of these procedures are targeted towards the symptoms of ischemic MR. Both disregard the
fact that the mitral valve itself is almost always in excellent health. It is simply being tethered
open by PMs displaced due to ventricular remodeling.
1.3 Proposed New Treatment
A new approach to MR treatment would be a major contribution to this field of research.
Experiments performed at the Cardiac Ultrasound Laboratory at the Massachusetts General
Hospital (MGH) point to a new type of therapy for LV remodeling[1]. The idea of correcting
ventricular remodeling with the application of an external mechanical device was tested. A
Dacron6 mesh was sutured onto a sheep's LV and a balloon was inserted under the mesh. The
balloon was then filled with water, creating an indentation in the LV at the location of the PMs.
This realigned the PMs with the mitral valve which allowed it to close more completely and had
5 Usually a pig's or cow's valve is used as a replacement.
6 Dacron is a brand of polyester fiber with high tensile strength, and is resistant to stretching and degradation by
chemicals or abrasion.
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a significant impact on MR. The problem with this static mechanical solution is that it increases
the stiffness of the LV wall and also reduces the LV's blood intake volume. This countered some
of the improvement in overall heart-pumping efficiency achieved by the MR reduction.
The MGH experiments highlight the need for an active device to compensate for
pumping inefficiencies due to MR. Ideally an active mechanical device on the heart's epicardium
would be able to create an indentation to displace the PMs during cardiac systole and then retract
during diastole so as not to obstruct the LV's inflation. The ultimate goal would be to create a
"patch" made from an artificial muscle technology. Such a patch could be applied directly to the
epicardium and would both relieve MR and also increase the pumping force that a damaged LV
can generate.
1.4 Study Purpose and Scope
This thesis presents the design and early development of an artificial muscle patch
(AMP) device to treat MR. Chapter 2 covers the development of an AMP simulation device
designed for use during a series of in-vivo experiments to proof the concept of an AMP. Data
gathered during these experiments concerning the pressure and motion requirements of an AMP
device is also presented. Chapter 3 discusses the development of an in-vitro model to test present
and future AMP device iterations. Chapter 4 covers the development of an AMP device based on
shape memory alloy, an artificial muscle technology. The final chapter summarizes progress
made toward AMP development and discusses future possibilities for research in this area.
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2 AMP Device Simulation
2.1 Background
While a static patch had been shown to alleviate ischemic MR and was a relatively
simple device to construct, the function of this patch was not very complex. Data from the
Cardiac Ultrasound Laboratory experiments with static patches also focused on the qualitative
analysis of the static patches' effects on the MR under observation. Few data exist on the extent
of myocardial displacement that the static patch was effecting or the force required to do so.
Furthermore, no data were available on the timing and speed of actuation that an active patch
should have relative to LV systole. Attempts to design an artificial muscle-based device from
these incomplete data would have required too much guess-work to establish the device's
operating parameters, leading to many failed attempts that would be both time consuming and
require the needless use of test animals. It was therefore decided that an artificial muscle patch
simulation device should be constructed in order to proof the concept of active patch therapy and
to gather as much quantitative data as possible to develop the missing design criteria required for
the creation of an AMP device.
2.2 AMP Simulation Apparatus
In order to make the data gathering results as reliable as possible, a mechanism for
effecting change to the LV wall having the least amount of variables was selected. Continuing
along the same lines as the Cardiac Ultrasound Lab's previous method[l], a fluid-filled balloon
held against the LV's exterior wall was chosen as the on-heart displacement element. The active
15
portion of the device would be a fluid pumping system (FPS) capable of receiving gated signals
from the test animal's heart and of filling and emptying the balloon at very high rates. 7 An
electronics package also had to be developed to receive a signal either from an electrocardiogram
taken directly from the test animal's heart or from an internal LV pressure monitor already in
place in the operating room, and transform this signal into a digital triggering pulse recognizable
by the fluid pump. The final element of the instrument was a series of sensors to measure the
pressure applied by the balloon to ensure sufficient displacement of the myocardium to relieve
MR.
2.2.1 On-Heart Elements
The Cardiac Ultrasound Laboratory's original balloon patch device was held in place
using a Dacron mesh sutured to the LV wall. This setup was satisfactory for a static device but
unsuitable for an active device, where its constant motion would cause location shifts. This
would not have provided good results since the effect of the patch observed in the Levine
experiments was very dependant on its location[1]. In order to solve this problem it was
necessary to build a frame, referred to as a base ring, which attached to the balloon and would be
in turn sutured onto the epicardial wall of the LV. A balloon that could be connected to the fluid
line coming from the pumping system would then have to be designed to properly fit into the
base ring.
7 Systolic contraction of the LV lasts approximately 180 ms for a heart rate of 2Hz (120 bpm) (standard heart rate
for a sheep during an in-vivo procedure)[12].
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2.2.2 Base Ring Version 1
The first iteration of this base ring was designed to hold a circular-shaped balloon. Its
parts were modeled in CAD (Figure 3a) then machined on a HAAS 3-axis CNC mill from 1.5
mm thick stainless steel sheet stock. Figure 3b shows the machined bottom two layers of the ring
assembly. Dimensional schematics can be seen in Appendix A, Figure 49.
a) b)
Figure 3: a) CAD assembly of Base Ring Version 1; b) Photo of machined main components of Base Ring
Version 1.
Based on the design and preliminary machining, and in consultation with the
cardiologists at the Cardiac Ultrasound Laboratory, it was decided that an oval-shaped balloon
8
would be more successful. As a result, further development of this iteration was halted before
completing any other element of this base ring design.
8
This decision was based on the Cardiac Ultrasound Laboratory's previous experiments using a static patch[1]. The
longer oval balloon covers a greater area of the LV's epicardium thus reducing the difficulty in trying to align the
balloon precisely with the PMs. It also does not deform a single point of the epicardium as much as a smaller round
balloon would which would put less stress on the base ring's sutures.
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2.2.3 Base Ring Version 2
In order to accommodate an oval-shaped balloon, a new base ring was constructed with
the appropriate shape. This iteration used a design and method similar to that used for version 1.
This oval base ring was designed as a three-layered device held together by Ml screws. Slots
were machined into the bottom layer's periphery to provide an easily accessible edge. This edge
could then be used to suture the assembly to the heart. The top layer was an oval 2.5 mm wider
than the periphery of the bottom layer's cutout. Its center was also partially milled out to provide
extra space for the balloon. The middle layer consisted of an oval ring segmented in two to allow
the balloon to be fitted and clamped between the top and bottom layers. Figure 4a shows the
CAD assembly of the oval base ring. Figure 4b shows each individual machined part while
Figure 4c shows the final machined assembly. Dimensional schematics can be seen in Appendix
A, Figure 50.
a) b)
Figure 4: a) CAD assembly of Base Ring Version 2; b) Individual machined parts of Base Ring Version 2.
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2.2.4 Balloon
Once the oval base ring was complete, a balloon of the same dimension as the ring's
inner cutout was assembled. The insert of the balloon was a nylon tube fitting that was ground
down to fit inside of the Teflon PFA tube coming from the FPS. The balloon material was taken
from two intra-aortic balloons provided by the Cardiac Ultrasound Laboratory. The intra-aortic
balloons measured 200 mm in length but only 85 mm from the tips down were used. Wet Surface
Gap Filling epoxy was applied to the threaded end of the nylon fitting, which was then inserted
into the open base of the balloon section. 250 pm wire was then wrapped tightly around the
portion of the balloon mated to the nylon fitting. Finally, flexible urethane epoxy was generously
applied on top of the wire and on the edges of the mated balloon section to cover any sharp edges
or wire endings. Figure 5 shows the assembled balloon. Two were built to ensure that at least one
of the assembled balloons would work properly.
Figure 5: Fabricated balloon for on-heart assembly.
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2.2.5 Assembly
Once the oval base ring and balloon were completed they were assembled in two steps.
The balloon was inserted between the two middle sections of the oval ring, and then the ring's
top layer was placed into position and secured by tightening the nuts on the M1 screws. Figure 6
shows the assembled on-heart portion of the simulation device.
Figure 6: Photos of the fully assembled on-heart assembly.
2.2.6 Fluid Pumping System (FPS)
In order for the system to function properly, the fluid pumping system would have to be
gated to the systolic portion of the LV's contractile cycle. As previously mentioned, systole
occurs over a 180 ms period in a test animal with a 2 Hz (120 bpm) pulse[12]. This meant that
the balloon needed to be filled and emptied in approximately 200 ms. This placed very high
force and velocity requirements on the pumping apparatus and limited the possible choices of
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mechanisms. The combination of a linear actuator pushing a syringe was chosen as the best
option given these requirements.
2.2.7 Linear Actuator
In order to select a linear actuator, calculations of force and velocity requirements had to
be performed. The volume required to fill the balloon that would be attached to the heart was
taken from the Cardiac Ultrasound Laboratory's prior in-vivo experiment using a similar-sized
balloon. On average, a balloon filled with 11 mL was successful at relieving MR[ 1]. Assuming a
syringe inner diameter of 20 mm,9 the linear actuator needed to have a travel of approximately
40 mm in order to displace the proper amount of fluid. 10 This number was increased to 150 mm
in order to have the option of using a syringe of a different diameter at a later time. Using these
assumptions, calculations were performed based on an estimate of the maximum pressure
required to displace the LV and on the Poiseuille Flow equation for the pressure drop across each
section of tube (Equation (1)) to determine the maximum force that the linear actuator would
need to produce to meet the requirements of this application. The entire calculation is shown in
Appendix B.
12-p -Q -LAP := + a-p -L
(1)7 -R
A summary of the linear actuator requirements is shown in Table 1. All values were
obtained from calculations shown in Appendix B.
9 Estimate based on available syringes.











requirements for linear actuator.
Possibilities were narrowed down to three manufacturers: Parker Daedal[13],
Aerotech[14] and Linmot[15]. The Linmot actuator was selected because of its superior
price/performance ratio. Although its positional resolution of 100 tm was inferior to its
competitors, it was still well within the tolerances for this application. Figure 7 shows the Linmot
PSO1-37x240 linear actuator.
Figure 7: Photo of the Linmot PS01-37x240 linear actuator used in simulation apparatus.
Another interesting feature of the Linmot actuator's controller is that it allows the user to
create custom-shaped position versus time waveforms for the Linmot linear actuator to execute.
These waveforms can be easily modified within the Linmot controller's software interface,
permitting modifications during the in-vivo procedure. This was especially useful since the LV's
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systolic and diastolic cycles are not of the same duration. 1 This feature made it possible to adjust
the position of the actuator at any given time to better match the characteristics of the test
animal's LV cycle characteristics.
Finally, the Linmot controller directly accepts a TTL1 2 triggering signal. This meant that
a substantial amount of programming could be bypassed by simply creating a hardware
electronic trigger'3 connected to a heart monitoring instrument.
2.2.8 Syringe and Mounts
A Popper & Sons Perfektum 50 mL glass syringe[16] was chosen for the water handling
portion of the pumping system. Its smooth action provided very little friction resistance and it
was rated for high-pressure applications.14 The syringe needed to be seated within an
immobilizing mount to ensure that the Linmot actuator did not apply any significant off-axis
force to the syringe's plunger. Otherwise the actuator accelerating at 50m/s 2 would quite easily
have shattered the syringe. Because the life expectancy of the syringe in this system was also
unknown an all-encasing mount was built to contain any critical failure. The syringe body was
measured and the mount was machined from two pieces of 25.4 mm thick Delrin. Since there
was a significant amount of variability in the syringe's exterior dimensions a certain amount of
sanding and filing was necessary for the mount to accommodate more than a single syringe.
Figure 8a shows the CAD assembly of the syringe mount. Figure 8b shows one of the machined
halves of the mount. See Appendix A, Figure 51 for dimensional schematics.
11I Systole occurs over approximately 80 ms, diastole over approximately 130 ms for a 2 Hz (120 bpm) heart rate.
Transistor-Transistor Logic (TTL) - A circuit element characterized by its ability to switch between high on-state
to a low off-state.
13 Details covered in the Electronic Gating System section on page 25.
14 No data were available on its maximum pressure capacity.
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b)
Figure 8: a) CAD assembly of Perfektum 50 mL syringe mounts; b) Machined Delrin component of
Perfektum syringe mounts.
Once the mount was completed, a coupler also needed to be machined to join the syringe
plunger to the Linmot actuator. The coupler was built in the same style as the mount. Figure 9a
shows the CAD assembly of the syringe-actuator coupler. Figure 9b shows the machined top and
bottom halves of the coupler. Dimensional schematics are available in Appendix A, Figure 52.
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a)
Figure 9: a) CAD Assembly of syringe-actuator coupler; b) Machined Delrin components of syringe-actuator
coupler.
2.2.9 Electronic Gating System (EGS)
The next requirement was that the fluid pump be "gated" to the LV's systolic cycle. Since
the Linmot controller was capable of accepting a 10 V TTL triggering signal, a hardware-based
electronic trigger was constructed to produce this signal from a heart monitoring instrument's
output.
The electronic gating system (EGS) was constructed around an MC14106BCP Hex
Schmitt trigger, an integrated circuit (IC) that produces a high output signal in its rest state but
switches to a low output state once the input signal passes the trigger's threshold.15 Since the
input signal would be relatively small, a non-inverting amplifier was placed in front of the trigger
to boost the signal's voltage. A potentiometer was placed in this amplifier to enable it to accept a
The exact threshold depends on the Schmitt trigger's supply voltage. In this case, a supply voltage of 10 V was
used making the triggering threshold 5.9 volts.
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wide range of input signals and also to adjust the triggering sensitivity of the EGS. An inverter
was placed after the trigger to provide a positive output signal and an amplifier was placed after
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Figure 10: EGS circuit diagram.
The circuit was soldered together onto a 45 mm by 45 mm prototype board and placed
into a custom circuit box machined from Delrin. Female BNC connectors were installed in the
Delrin box and connected to the input and output of the circuit. Female banana jacks were also
installed on the box to accept the power supply lines for the circuit elements. Finally, a threaded
bolt was inserted in the bottom of the box to allow it to be screwed down into an optical table.
Figure 11 shows the EGS circuit box.
26
Figure 11: Machined DeIrin EGS circuit box.
2.2.10 Sensors and Data Acquisition
Finally, sensors were added to the AMP simulation apparatus in order to gather data on
the active patch's force and extent of displacement. Two sensors were inserted into the path of
the fluid line between the fluid pump and the balloon. A flow meter was placed in series at the
syringe's output to measure the flow of water while the FPS was pumping. A pressure transducer
was placed in parallel with the pump-to-balloon line to measure the pressure inside of the fluid
line. The internal line pressure varied cyclically when the FPS was active but the pressure
transducer would pick up any external pressure applied to the balloon. During the in-vivo
procedure, this rise in internal line pressure corresponded to the pressure required to displace the
LV wall. This last could be calculated from the recorded pressure using the Poiseuille flow
equation (Equation (1)).
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The two sensors' outputs were in the form of a voltage signal on a 0 to 5 V scale. Both
were connected through a BNC-2 110 connection box to a National Instruments 6062E Data
Acquisition (DAQ) card in a laptop computer. A Visual Basic interface16 developed in Visual
Studio .NET[17] was used to control the DAQ card's recording functions.
2.2.11 Apparatus Assembly
Each element of the simulation apparatus was mounted onto a 900 mm by 600 mm
optical table and the elements connected together. Tube sections between the syringe and sensors
were kept to a minimum length, Teflon tape was applied to all threaded sections of NPT-tube
connectors and gap-filling epoxy was applied to all tube connections to ensure that no air would
infiltrate the line. Finally, a im length of Teflon-PFA tube was used to connect the apparatus to
the on-heart assembly. Figure 12 shows the simulation apparatus fully assembled.
Figure 12: Simulation apparatus mounted onto its optical table.
16 VB interface was created by Michael Garcia-Webb of the Bioinstrumentation Laboratory.
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2.3 In-Vivo Experiment I (Performed June 15th, 2003)
2.3.1 Background and Preparation
Preparation for the in-vivo procedure began 12 weeks prior to the procedure date.17 The
sheep under observation had certain coronary arteries ligated to obstruct blood flow to the LV
and create an infracted area. The sutures used to ligate the coronaries were left in until the in-
vivo procedure so as to better reproduce the characteristics of a chronically infracted LV. This
preparation was conducted by Dr. Luis Guerrero of the Cardiac Ultrasound Laboratory.
In the days prior to the in-vivo procedure, a series of tests were carried out to gauge the
FPS's performance under various conditions that might be encountered during the upcoming in-
vivo procedure. It was decided to use a k/2 sine wave as the position versus time output
waveform for all tests. The amplitude of the waveform was used to modify the volume pushed
into the balloon by the actuator while the speed of each pumping action was controlled by the
period of the sine wave. The Linmot controller's software was especially useful for testing the
FPS's limits this since the actuator possessed internal encoders that the software used to plot the
output waveform against the actual position of the actuator. This made it possible to detect what
maximum heart rate and volume displacement were possible without the actuator lagging or the
fluid lines taking in air bubbles.1 8 Most importantly, baseline pressure variations for the system
pumping at different volume displacements were recorded. It was necessary to do this prior to
the experiment since the balloon device would immediately be sutured to the sheep's LV once
the procedure began. These baseline data would be used in post-procedural data analysis to
17 While the standard preparation time for a chronic model infarct study procedure is eight weeks, due to difficulty
in obtaining all of the simulation apparatus equipment, a four-week delay was incurred. This delay would not have
affected results.
18 All fluid line connections were sealed with silicone and/or water-rated gap-filling epoxy, but it was discovered
that when the actuator passed a certain operating frequency the integrity of the connections was compromised by the
intense pressure variations and air would infiltrate into the fluid lines. Below this frequency, no significant air
infiltration was detectable.
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compare baseline pressure variations in the fluid line with the pressure variation when the
balloon was applied against the LV.
The wiring and equipment of the simulation apparatus was simplified as much as possible
as the entire setup needed to be brought to the Cardiac Ultrasound Laboratory at MGH for the
procedure. The optical table where the pumping system was bolted was placed on top of a cart
with all of the support equipment (power supplies, Linmot controller and oscilloscope) placed on
the carts lower shelf.
2.3.2 Summary of Procedure
The actual procedure lasted approximately six hours. The equipment described above was
transported to MGH, all electrical connections were made and the fluid line was filled with water
to remove all air from the system. During this time, the sheep was brought into the operating
room, sedated, prepped and its thoracic cage was opened to expose the heart. At this point the
sheep's heart required two hours of preparation (discussed in the following section). The cart
was then brought into the OR, the EGS was connected to an EKG monitor and the balloon device
was sutured onto the sheep's LV wall. Tests were run with the FPS used first to statically fill the
balloon and record the pressure produced against the balloon by the heart's pumping. This also
served to see what volume of water had to be pushed into the balloon to produce a significant
change in MR. Once this was complete, the system was set to pump on trigger. Figure 13 shows
the on-heart elements sutured to the sheep's LV.
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Figure 13: On-heart elements sutured to LV epicardium during first in-vivo procedure.
After approximately 4 hours of testing, during which the sheep fell into cardiac arrest and
required defibrillation to re-stabilize, the sheep's heart function had become too weak for any
further experimentation data to be reliable and the procedure was halted.
2.3.3 Issues Encountered
It was discovered immediately after opening the sheep's thoracic cage that its heart had
not developed the extent of ischemic MR required for the experiment. Two more coronary
arteries were ligated to cause further ischemia in the LV. This led to the formation of some MR
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but it was sporadic and the sheep's heart function became quite weak due to the added trauma of
a second ligation procedure. This made all observation of MR during the procedure problematic
and generally cast doubt on the validity of the results obtained.
Another minor issue was the source of the EGS triggering signal. Shortly before the
procedure it was decided to take the triggering signal from the heart's sinoatrial (SA) node by
attaching a lead directly to it. This should have produced a trigger signal that was approximately
30 ms before LV systole[12], giving a certain buffer of time before the FPS needed to be
activated. Once in the OR, however, receiving a clear signal from the SA node or from the LV
was difficult therefore the EGS was connected directly to an EKG monitor through a BNC cable.
Finally, the balloon's base ring was not the ideal shape for such a procedure. The pocket
where the balloon was sitting was too deep, which restricted the balloon's maximum protruding
distance into the LV. In order to achieve some level of MR relief it was necessary to place a 5
mm thick backing made from electrical tape to further extend the balloon. Figure 14 shows this
addition to the base ring.
Figure 14: Addition made to Base Ring during in-vivo procedure 1.
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2.3.4 Data Acquired
Many different volumes and frequencies were tested by adjusting the output waveform's
characteristics. Pressure and flow data were recorded for each waveform used. Because of the
poor condition of the test animal, none of the echocardiograph recordings were of particular
benefit. Since persistent MR could not be established, it was impossible to discern whether the
apparatus was performing according to theoretical predictions. The most relevant data extracted
from this procedure were related to the simulation apparatus itself. Recordings of the linear
actuator's actual position versus its demanded position (X/2 output waveform) were taken while
the on-heart elements were sutured to the LV epicardium and the FPS was pumping on trigger.
The actual position did lag significantly when the output waveform was set to a period of 250 ms
or shorter, but this speed of actuation did retract the balloon before the end of systole. Once this
was observed, the waveform was rejected. A waveform with a period of 400 ms was found to
work best.19 Figure 15a shows the actuator's lag with the 200 ms period waveform. Figure 15b
shows that the actuator still lags slightly behind the demand waveform. This confirms that there
is a certain variation introduced by the actuator in the timing of the balloon's inflation within the
operating range used during the procedure.
19 A longer-period waveform would have inflated the balloon too slowly.
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Figure 15: Comparison of X/2 output waveform versus actual actuator position: a) 200 ms period waveform;
b) 400 ms period waveform.
Pressure and flow data were also recorded both before the on-heart elements were sutured
to the LV and while they were being tested. The flow data obtained showed that the sensor
lagged significantly behind the FPS' actuation. This was due to the inability of the flow sensor's
turbine mechanism to keep up with the rapid changes in flow rates and directions being
produced. The pressure data were not reliable because of the aforementioned issues encountered
during the procedure. They were therefore discounted from further analysis.
2.3.5 Discussion of Results
As previously discussed, the state of the sheep's heart was such that most if not all of the
MR-affecting data are suspect since persistent MR could not be established. It was impossible to
tell if the MR was actually being relieved by the balloon device's inflation or if improvements
were due to temporarily-improved heart function. As such, no conclusion about the balloon's
effect on the sheep's MR can be established.
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Despite its limitations, several significant pieces of information were extracted from this
procedure. First, the linear shape of the base ring unnaturally distorted the LV's shape while the
LV was at rest. All of the surgical staff agreed that a base ring better fitted to the heart's
curvature would improve both device and heart function.
Another valuable observation was that the output waveform executed by the FPS needed
to be optimized to better match the LV's motion. The k/2 sine wave used failed to account for
the delay due to inertia that occurred during the transition between systole and diastole. This
resulted in a premature retraction of the balloon prior to the completion of the LV's contraction
and allowed some MR to occur before diastole. Overall, the k/2 sine wave was not ideal for this
application since its adjustability was limited. An increase in the period would lengthen the
balloon's total inflated time but would also increase the delay before the balloon was at full
inflation. A waveform with a rapid rise followed by a plateau at the balloon's full inflation level
and a rapid drop would have better followed the heart's actual movements.
Another element that caused some data discrepancies was the use of an EKG signal as the
triggering signal for the EGS. The EKG waveform was erratic which caused the EGS to
sometimes trigger the FPS too late or not at all. A better source for the triggering signal would
have to be found for the ensuing in-vivo study.
In light of these shortcomings, the pressure values obtained during this in-vivo
experiment are unreliable. By changing the output waveform, base ring configuration and timing
of the FPS' activation, this value could vary significantly. Another experiment addressing the
above issues was performed to obtain more credible data.
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2.4 In-Vivo Experiment 2 (Performed August 11t, 2003)
2.4.1 Improvements to Instrumentation
For the second in-vivo experiment, all of the lessons learned in the previous in-vivo
procedure were used to improve the simulation apparatus. The most important change to the
device was the creation of a new base-ring design. This new base ring held the balloon much as
the original ring had but its suturing loops were extended away from the balloon in its long
direction to reduce the amount of stress placed on the sutures when the balloon was inflated. The
ring was also curved to approximate the LV's exterior contour. This design was built on a
Stereolithography machine (SLA) and had only two parts. The first was an oval frame with four
arms extending from the oval's ends. These arms ended with small oval loops where the sutures
could be attached. The second part was a backing that fit on top of the oval frame to hold the
balloon in place. Figure 16 shows the CAD assembly of the new base-ring design.
Figure 16: CAD assembly of Base Ring 3 used for second in vivo procedure.
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Based on the first in-vivo study's experiences and on the general unpredictability of
biological systems, an entire series of frames and backings with different characteristics were
prepared so that the best-fitting frame and backing could be fitted to the new test animal's heart.
Various frames were built with suture loops extended outwards to different distances and with
extending arms arrayed in asymmetrical configurations. Curved protrusions were added to a
series of backings in order to increase the maximum depth of indentation that the balloon could
effect. Backings with protrusions ranging from 2 to 5 mm were prepared. Finally, two sets of all
frame and backing designs were built, each with a different curvature. Figure 17 shows the entire
series of devices prepared for the procedure. Dimensional schematics can be seen in Appendix
A, Figure 53 and Figure 54.
a) b)
Figure 17: Series of devices prepared for second in vivo procedure: a) Base frames; b) Backings.
Improvements were also done to the FPS' output waveform. A new waveform
configuration was created to replace the k/2 waveform from in the first experiment. This new
waveform used a k/4 section of sine wave to provide the rise and fall in amplitude (position) of
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the waveform. A plateau was inserted into at the waveform's maximum amplitude to extend the
balloon inflation period. This waveform was custom configured for this particular application.
Due to the time required to make adjustments to this waveform, a series of preconfigured
waveforms were prepared prior to the in-vivo experiment. These waveforms varied in inflation
and deflation time (30 ms to 50 ms) and also in the length of their plateau (50 to 200 ms). Figure
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Figure 18: Output waveform prepared for second in-vivo study.
2.4.2 Summary of Procedure
Logistically, the second in-vivo study proceeded in the same way as the first. The
simulation apparatus was moved to MGH and set up outside of the OR. During this time, the
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sheep was brought into the OR and prepared. The sheep's heart was examined by
echocardiography before beginning any testing. It was observed that the sheep had developed a
much more significant amount of chronic MR than the previous test animal. The base ring
frames and backings were arrayed before the surgeon, who chose the best fitting pair for the test
animal's heart (Figure 17, frame number 3 and backing number 3). The on-heart assembly was
then sutured onto the LV and connected to the FPS. The EGS input was connected to an LV
pressure monitor that received its data from a Millar catheter20 [18] inside of the LV. This
provided a signal directly related to the motion of the LV. Although the use of this signal meant
that the FPS would activate when the LV was already beginning systole, the clarity of the signal
from the Millar catheter outweighed the slightly delayed triggering of the FPS. Furthermore, the
ability of the linear actuator to accelerate extremely rapidly2 1 was used to compensate for the late
triggering. Figure 19 shows the EGS' trigger output and the Millar catheter input.
20 A Millar catheter is a pressure measuring device that consists of a pressure transducer placed at the distal end of
the catheter. This allows the transducer to be inserted directly into the LV to obtain precise LV pressure
measurements.
21 The Linmot PSOI-37x240's maximum acceleration is 268 m/s2.
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Figure 19: EGS trigger output from Millar catheter input.
Initial tests were performed to determine the balloon inflation volume required to affect
the sheep's MR. Once this was determined, testing began with the EGS controlling the FPS.
Figure 20 shows the on-heart elements sutured to the sheep's LV while the balloon is at full
inflation.
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Figure 20: On-heart elements sutured onto LV epicardium during second in-vivo procedure.
2.4.3 Data Acquired
The same tests were performed during the second in-vivo study as in the first procedure.
The output waveform and actual position were plotted while the FPS was pumping on trigger to
verify that the actuator did not lag behind its demand position. Figure 21 shows that the actuator





Figure 21: Comparison of output waveform demand position versus actual actuator position for second in-
vivo study.
Pressure and flow data were again recorded to measure the balloon countering pressure
(BC pressure (PBc)) of the LV with the new simulation apparatus configuration. Figure 22 shows
the pressure measurements taken while the FPS was pumping on trigger before suturing the on-
heart elements to the sheep's LV. They provide baseline data for the FPS's function independent
of any contribution from the LV wall against the balloon's surface. Figure 23 shows the pressure
measured after the on-heart elements were sutured onto the LV epicardium. Flow data were also
taken for the first few series of measurements but a malfunction in the flow sensor prevented
further data recording. Fortunately these data were not critical to the performance analysis.
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Figure 22: Pressure (blue) and Trigger Signal (red) with FPS pumping on trigger prior to the on-heart
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Figure 23: Pressure (blue) and Trigger Signal (red) with FPS pumping on trigger and the on-heart elements'
sutured on the LV.
Equation (2) was used to calculate the BC pressure (PBc) from the data in Figure 22 and
Figure 23. Variations in pressure (AP) were calculated by subtracting the height of a valley
minimum from the height of the following peak's maximum. The values from a data set were
averaged and compared to the averaged value from the baseline data set to obtain the BC
pressure. The baseline pressure curve was compared in this manner against four measurements
taken during the course of the procedure with output waveforms of different periods. A AP was
calculated for each one and the baseline AP was subtracted from them, yielding a series of BC
pressure values. All AP and PBC values are shown in Table 2. On average the LV exerted 10.31


























Table 2: Recorded AP values throughout second in-vivo procedure.
10.31
The most intriguing observation from the second in-vivo study was that the active patch
device simulator was successful at relieving the sheep's MR. While the system was pumping on
trigger it could be seen on an echocardiograph that the sheep's MR would consistently decrease.
If the system was halted, the MR would return almost immediately. Figure 24 shows an image
recorded on an echocardiograph of the sheep's LV and LA during systole with the simulation
device inactive. The blue plume representing blood returning through the open mitral valve is
quite prominent.2 2
22 An echocardiograph set in color vector mode such as this one displays all flows moving towards the scanning
probe in red and all flows moving away from the probe in blue.
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PBC =(2)
OUTPUT WAVEFORM AVERAGE AP STANDARD PBC
PERIOD (KPA) DEVIATION
Baseline 20.20 0.61 -
500 ms -1 33.34 0.64 13.15
500 ms -2 30.17 0.40 9.97
400 ms 26.49 0.37 6.29
200 ms 32.01 0.53 11.81
Figure 24: Echocardiograph image recorded during the second in vivo study showing prominent MR with the
active patch simulation device inactive.
Figure 25 shows an image taken as the balloon was inflating on trigger with the heart.
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Figure 25: Echocardiograph image recorded during the second in-vivo study showing the AMP simulation
device's balloon inflating on trigger with ventricular systole.
In comparison to Figure 24, Figure 26 shows an echo image of the sheep's LV and LA
during systole. The MR plume is not present as it was in Figure 24. The MR was consistently
reduced or eliminated each time the simulation device was activated.
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Figure 26: Echocardiograph image recorded during the second in-vivo study showing relief of MR by the
active patch simulation device.
This relief of MR was obtained by filling the balloon with 8 mL of fluid. Post-
operatively, this volume was injected back into the balloon in order to measure the depth of
protrusion that the balloon was creating. Figure 27 shows an image taken with the balloon filled
with 8 mL of fluid. From this image, the depth of protrusion was measured to be 12 mm.
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Figure 27: Balloon filled with 8 mL of fluid.
2.4.4 Discussion of Results
The healthy state of the test animal's heart greatly contributed to the overall success of
this second experiment. Whenever the simulation device was inactive, the echocardiogram
showed the MR consistently returning to its original level (prior to installing the base ring onto
the LV). This made the effects of the simulation device on the MR quite apparent.
Although there was a significant amount of variation in the calculated BC pressures for
different attempts, this experiment was very successful in establishing a lower bound for the
pressure that an artificial muscle would be required to produce to affect MR in a sheep's LV.
Most importantly, the success of the active patch simulation device at relieving MR in




There are a number of potential uses for the AP simulation apparatus in future research. It
could be used to test various attachment configurations for an implantable device. One of the
important issues to resolve for such a device is what configuration of suture points would
produce the most efficient LV deformation to relieve MR. The AP simulation system could be
used with a variety of base ring configurations to study this problem experimentally. Another
potential avenue of research is into the timing of the FPS activation and duration, which could be
further studied to enhance the output waveform and provide the most efficient MR relief. These
data would provide a significant contribution to the development of a future AMP apparatus.
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3 In Vitro Model Development
3.1 Background
Cardiology experiments are traditionally conducted in-vivo on sheep, pigs or dogs. It is
currently the only method to test how a particular treatment or device will behave in a living
system, which has many more variables than can be accounted for in a bench-top laboratory
setting. In the case of novel instrument development, however, the laboratory development of an
in vitro model offers several benefits. Even simple design problems can take many hours to
correct and must therefore be dealt with prior to the start of an in-vivo procedure where time is
critical. Furthermore, sensors of various types such as force transducers, motion sensors and even
visual recording equipment can be integrated into the model to gather a baseline of experimental
data that can be later compared to in-vivo results. In light of this, the development of an in-vitro
simulation model for intermediary testing prior to an in-vivo procedure is advantageous for
humanitarian, cost, and research reasons. Such models have been used in the past to show the
particular mechanism of MR to great effectiveness[19]. With an in-vitro model to consult, almost
all of the instrument's parameters can be resolved to a greater degree of certainty without the risk
of a failed in-vivo procedure.
3.2 Design and Manufacture
In order to design properly an effective in vitro sheep heart model, it was necessary to
base the dimensional criteria on an accurate representation. This was provided by Professor Peter
Hunter of the Bioengineering Institute at the University of Auckland in New Zealand. Professor
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Hunter's group developed a finite element model of the ventricles of a pig's heart (essentially the
same as a sheep's heart) for organ function simulation and analysis with the Bioengineering
Institute's in-house developed CMISS mathematical modeling software[20]. One of the boons of
the CMISS software is that it is able to export its models in various formats such as the STL
format23 used by Stereolithography (SLA) machines. After receiving the file, the model was
prepared and manufactured in high resolution mode24 over an 18-hour period. The resulting
model is shown in Figure 28.
b)
Figure 28: SLA manufactured model of a pig heart's ventricles: a) Side view; b) Top view.
This SLA-printed heart could not be used directly as an in-vitro model because of the
inflexibility of its walls; however, it was an excellent starting point and, with some
23 A file in STL format is essentially a cloud of points mapping the surfaces of the model. From these points, the
surface of the heart is extrapolated.
24 High resolution mode for a Viper Si2 SLA has 50 im thick layers and a laser beam diameter of 75 prm. Low
resolution mode uses a 100 pm layer thickness with a 200 pim beam diameter.
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modifications, could serve as the foundation for the final instrument. The most important change
required was to use a molded flexible polymer compound to replace the LV section of the model.
For immediate purposes, the SLA heart model was used to size the various devices being
developed for in-vivo testing and as a basis for sizing the following iteration of the in-vitro
instrument.
3.3 Version 1.0
The development of a comprehensive in-vitro instrument would have required a
substantial amount of time. It was decided that developing a simpler version that could be used
sooner was best, and that the task of designing and building a more complex version could be
addressed at a later time. The simplified design would be a half-ellipse of similar dimensions as
the SLA model's LV and would be made from a polymer molding compound that would best
match the properties of a sheep's LV wall.
3.3.1 Design
The first step in developing this iteration of the in-vitro instrument was to design a
negative mold in the shape of the desired LV ellipse 26 that was appropriate for the chosen
molding compound. A flange was also added to the ellipse's edge so that it could easily be
clamped into a holding frame. The mold was created in CAD, then manufactured using an SLA.
Figure 29a shows the CAD assembly of the first version of the LV ellipse mold. Figure 29b
25 See data and calculations from Section 2.4.3.
26 The actual shape of the model is not perfectly elliptical. The peak of the ellipse was offset to one side to better
approximate the geometry of a real sheep's heart. The result, as can be seen in Figure 29, is more of a half egg
configuration but for simplicity's sake, it will still be referred to as the LV ellipse.
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shows the resulting SLA part. All dimensions and schematics can be viewed in Appendix A,
Figure 55. The mold was designed to have interchangeable male sections. The female section set
the exterior dimensions of the mold while the male section could be modified to vary wall
thickness (thus adjusting the flexibility of the ellipse's wall) and also to accommodate the
different molding compounds and techniques to be used (casting and press-molding). It was
designed to be used as a press mold for a high viscosity Silicone putty compound. As such, it
was designed with much thicker walls than would be necessary for a regular casting mold in
order for it to withstand the forces needed to press the silicone-epoxy paste into the mold shape.
a)
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Figure 29: a) CAD assembly of the half ellipse mold Version 1. b) Photo of the SLA manufactured mold
pieces.
3.3.2 Manufacture
Two types of molding compounds were tested in this mold. The first was President
Putty/Putty Soft from Coltene[21]. It is a high-viscosity, fast-curing A-silicone-based putty
designed to be used in a press mold for dental applications. The second was a low-viscosity, 24-
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hour addition-curing silicone rubber made by Silicones, Inc.[22] designated P-4. The properties
of the two compounds are listed in Table 3.
P-4 COLTENE PUTTY
Mixing Time - 45 s
Working Time 2 to 3 hours 130 s
Setting Time 16 to 24 hours 255 s
Strain in Compression - 2.0% to 3.0%
Shore Hardness 41 -
Tensile Stregth 4.82 Mpa -
Elongation 150% -
Recovery after deformation - 99.0%
Table 3: Properties of compounds used to mold the LV ellipse.27
The advantage of using the Silicone putty was that its curing time was approximately 5
minutes. As such, any mistakes resulting in an inadequate molding could be addressed without a
significant time penalty. The disadvantages were that it cured so quickly that its working time
was quite short (approximately 90 seconds), resulting in the first few iterations being
unsatisfactory. In addition, the physical properties of the putty compound were not ideal,
meaning that it would tend to yield stiffer ellipses than were desired. On the other hand, the P-4
silicone rubber required much more time, as it had to be vacuumed both prior to and after
pouring into the mold to remove all air bubbles from the mixture. It also required 24 hours of
curing time.
The different compounds required two slightly different types of molds. The Silicone
putty needed to be pressed into the ventricle shape. This required the mold to be very sturdy. In
light of this, the female section was designed with thick sidewalls and the male portion was
designed with a flat top so that they could both easily be pressed together. The P-4 compound did
27 Properties taken from the manufacturer's data sheet provided with each compound. Note that because of the
provenance of the Coltene putty from dentistry, it was difficult to obtain standard mechanical specifications.
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not demand any significant physical properties from the mold but did require that the top have
many venting holes and a receptacle section around the venting holes to capture the excess
mixture that seeped out while pressing the mold together and also while in the vacuum phase of
the process. This enclosure also ensured that enough material was present to fill any voids that
might form while moving the mold. Wall thickness for both moldings was 4 mm. All
components for the mold were built using SLA.
3.3.3 Silicone Putty Molding
The Silicone putty LV ellipse was molded by mixing equal parts of the putty's two
components together and kneading them by hand for approximately 60 seconds. The combined
paste was then placed in the valley of the female mold and roughly distributed around the ellipse
wall to help the mixture spread more easily during the actual molding process. (Mold release was
generously applied to both parts of the mold before mixing the paste.) The male section of the
mold was inserted into the female section and the mold parts were turned upside-down and
pressed together by placing an 85 kg weight on top of them for 60 seconds.28
The first two attempts at molding the LV ellipse with the Silicone putty yielded poor
results due to the mold either being too full and/or not being pressed enough during the working
time, or not being filled enough and the compound not spreading to the flange's edges. After
these two failed attempts, a successful iteration was created. The resulting molding is shown in
Figure 30. This type of compound does not hold air bubbles within the mixture, however certain
thin regions and voids existed where the mold could not be pressed together sufficiently enough
before the compound set.
28 The experimenter stood on top of the mold.
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Figure 30: Isometric view of Silicone putty LV ellipse molding.
3.3.4 P-4 Silicone Rubber
Molding a ventricle using the P-4 silicone rubber was far less time critical than with the
Silicone putty. The silicone rubber and hardener were mixed together in a 10:1 ratio (by weight),
stirred thoroughly for 5 minutes then placed in a vacuum chamber for 15 minutes to remove the
air bubbles from the mixture. A generous coating of mold release was applied to both parts of the
mold during this time. When bubbles no longer rose to the surface of the mixture the silicone
rubber was poured into the female half of the mold and the male half was pressed into it and
screwed in place to align it properly. The mold was then placed back into the vacuum chamber
for 45 minutes to remove all of the air bubbles contained within the mold. The mold was then
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left to cure for 24 hours. The P-4 compound yielded a very good LV ellipse on the first attempt.
Figure 31 shows the resulting molding.
Figure 31: P-4 Silicone-Rubber molding of the in-vitro LV ellipse.
3.3.5 Ventricle Frame
Once the LV ellipse moldings were complete, the holding frame that would immobilize
the LV ellipse and provide a steady base for experimentation was designed and manufactured.
The frame was built to clamp the flange of the LV ellipse. A substantial protrusion was also
added to one side of the frame to provide a location to fit the frame into a vise. The frame was
manufactured on an SLA. Figure 32a shows the CAD assembly of the frame and LV ellipse.








Figure 32: a) CAD assembly of the half ellipse in vitro model b) Photo of the SLA-manufactured frame and
silicone rubber molded half-ellipse assembled for use.
3.3.6 Force Measurements and Redesign
Force measurements were taken at the peak of the ellipse by pressing a force transducer
against the immobilized LV ellipse. The measurement was taken once the ellipse had been
displaced inwards by 12 mm. 29 Figure 33 shows the experimental measuring setup. The results
obtained from these measurements on both of the LV ellipses can be viewed in Table 4.
29 Displacement figure was taken from the experimental value obtained from in-vivo experiment 2 (Section 2.4.3).
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Figure 33: Experimental setup for force measurements of the P-4 Silicone-Rubber LV ellipse.
COMPOUND FORCE (N) AREA (M2) PRESSURE (KPA)
Silicone Putty 52.57 3.81 E-04 138.05
P-4 Silicone Rubber 12.83 3.81 E-04 33.69
Table 4: Results from force measurements of LV ellipse.
The results show that the Silicone putty ellipse is decidedly not flexible enough to serve
as a good LV simulation. The P-4 ellipse was also not quite flexible enough but was overall a
much easier compound to work with for this particular application. It was decided to create a
new molding using the P-4 compound but to reduce the wall thickness of the ellipse in order to
increase its flexibility and improve its performance relative to a real LV. A new male half was
created with an SLA to give the molding a 2.75 mm wall thickness. A new ellipse was molded
and the force measurements were redone on this version. This version only required 3.06 N (8.04
kPa equivalent) of force to displace its wall by the proscribed 12 mm, making it a much better
instrument for its intended purpose.
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3.4 Future Work
Future work to develop an in-vitro model of an LV could be very far-reaching. An ideal
model would have a soft tissue-like reproduction of an entire heart along with pumps to actuate
its cavities. For the active patch application, multiple position sensors could be embedded into
the LV wall to allow a real-time observation of LV deformation with and without a patch device
present. The pumps could also have alterable rates and strokes in order to modify the pumping
rate, size and internal pressure of the simulated LV. This would provide excellent testing for a
device that needs to function under various conditions (such as while a patient is exercising).
Such a device could also be easily modified for use in research on other cardiac conditions
currently under study, such as an enlarged heart.
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4 Shape Memory Alloy AMP Prototype Development
The final goal of this research project was the design, development, and testing of an
active muscle patch based on shape memory alloy technology. This chapter introduces that
technology, reviews the designs considered, and discusses the results of the two AMP iterations
developed. The section ends with future plans for research in this area.
4.1 Background on Shape Memory Alloy
Shape memory alloy (SMA) is an alloy that undergoes a phase transformation in its
crystal structure that changes the material's shape and properties when it is heated above a
particular temperature[23]. When the SMA is brought above this transition temperature it
changes from the Martensitic state to the Austenitic state. This is characterized by a change from
an acicular crystal structure of Martensite to the face-centered cubic structure of
Austenite[24,25,26]. Martensite is weaker than Austenite but it is a very elastic form of the NiTi
alloy. Its deformation stress ranges from 70 MPa to 140 MPa3 0 but it can absorb up to 8%
recoverable strain. In comparison, Austenite is not elastic but its yield strength ranges between
240 MPa and 690 MPa[23]. The transition temperature of the alloy varies depending on its
proportions of nickel and titanium. The SMA wires used in this series of experiments were
FlexinolTM wires purchased from Dynalloy Inc.[27]. This variety of SMA is a Nickel and
Titanium alloy that has a transition temperature of 70 C3 1 .
30 The exact value depends on specific alloy content.
31 All future references to Shape Memory Alloy (SMA) wires are to the FlexinolTM Ni-Ti alloy.
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4.2 Potential Designs
Many designs for the use of SMA wires in a semi-implantable AMP device were
conceived. The greatest design challenge for an SMA device was to amplify the SMA's
displacement (4% of its length) in order to produce a 12 mm protrusion32 into the LV.
Furthermore, an implantable device had to meet certain size constraints in order to properly fit
into the sheep's chest cavity and not obstruct normal heart function. A summary of the
established criteria is shown in Table 5.
CRITERIA VALUE
Size (approx.) 60 mm length by 30 mm width by 10 mm height
Operating Frequency 2 Hz 3
LV Protrusion Depth 12 mm
Minimum Protrusion Pressure Output 13.15 kPa34
Table 5: Summary of design criteria for SMA prototype.
Most designs were eliminated due to impracticality. Two designs were taken to early
development. The first used a lever to achieve its displacement magnification while the second
used a sliding mechanism to bend a thin piece of stainless steel shim.
4.2.1 Lever Prototype
4.2.1.1 Design
The first design to be prototyped was based around a lever in order to achieve the 12 mm
protrusion required to affect MR in the LV. The lever ratio to obtain 12 mm of protrusion was
calculated and a lever was designed that would fit within the size constraints of an implantable
32 Calculated from the experimental data in Chapter 2.
A 2 Hz (120 bpm) heart rate is the upper norm for a stabilized sheep under anesthesia.
34 13.15 kPa was the highest value obtained from the second in vivo procedure (Section 2.4.3). The highest value
was used in order to set a conservative lower bound for the design criteria.
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device. A curved surface or paddle at the lever's contact point was also added to the lever in
order for it to depress more evenly a larger region of an LV. An analysis was performed to
determine the optimal lever arm angle and the force required from an SMA wire. This helped
determine the proper diameter SMA wire. According to the calculations shown in Appendix C, a
wire producing a force of approximately 6N was required. This corresponded to an SMA wire of
200 tm in diameter.35 A frame to hold the lever and the SMA wires was then designed. Two
counteracting SMA wires were incorporated into the design. The first wire would extend the
protruding lever while the second would retract it and reset the device. The resetting wire would
need to be wound around a pulley for it to attach onto the lever from the opposite side. Figure 34
shows the CAD assembly of the Lever prototype. Dimensional schematics can be seen in
Appendix A, Figure 57.
Figure 34: CAD assembly of lever prototype.
35 Calculation made from manufacturer's published specifications.
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4.2.1.2 Manufacturing and Assembly
The lever prototype's components were manufactured on an SLA. All parts were
assembled and the SMA wires were tied through two holes to the lever's arm and run to two 1.6
mm screws on the frame's end. These also served as the electrodes where power supplies could
be connected. Figure 35a and Figure 35b show the final assembly while Figure 35c shows the
device with its lever deployed.
a) b)
c)
Figure 35: a) Top view of manufactured assembly; b) Side view of manufactured assembly; c) Lever
prototype with lever deployed.
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4.2.1.3 Testing
Testing of the lever design was done by connecting two power supplies to the device, one
to each of the 1.6 mm screws. The two wires were of different length and therefore required
different voltages to achieve a 1 A activation current. The protrusion wire's electrical resistance
was calculated at 2.36 Q 36 while the resetting wire's resistance was 1.57 Q.37 The protrusion
wire therefore required 2.36 V while the resetting wire required 1.57 V to reach 1 A according to
Ohm's law (Equation (3)).38
(3) V=RxI
During testing, the device achieved approximately 12 mm of protrusion depth, but the
activation of the SMA wires was very slow relative to the desired operating frequency of an
implantable device. The slow activation also meant that the wires would convey more heat to the
SLA resin and would melt it wherever the two came into contact (such as the pulley and the
attachment points of the lever).
4.2.1.4 Status
At present there are no plans to further the development of this prototype, although its
principles are sound. The design could be improved and problems addressed at a later date.
36 Note that the electrical resistance of an SMA wire changes as it transitions from Martensite to Austenite. This
value can only be used as a baseline for the voltage requirement.
37 Based on manufacturer's published specifications[27].
38 1 A maximum sustained operating current obtained from the manufacturer's published specifications for 250 ptm
wire[27].
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4.2.2 Bowing Shim Prototype
4.2.2.1 Design
The second prototype to be developed used a mechanism that would slide upon SMA
wire activation, causing a thin piece of stainless steel shim to bow outwards. The advantages of
this design were that the bowing shim would by nature provide a fairly large, curved, protruding
surface, and more importantly, the bending of the shim through lateral compression would
inherently provide a self-resetting element for the SMA wires. The disadvantage of this design
was that there was no significant mechanical amplification of the SMA wires' displacement.
Longer wires would need to be incorporated into the design in a shoelace configuration, wound
around a rod on each end of the frame. This configuration enabled the wire to be crossed five
lengths of the frame giving each wire a length of 300 mm. A Macor 39 rod was used on each end
of the frame instead of SLA manufactured pulleys in order to avoid the melting issues
encountered with the lever prototype. The shim would be held by two end caps. One would be
fixed to the inside of the frame by a rod running through it, allowing the cap to swivel as the
shim bows outwards. The other cap would be free to slide in a track on the inside of the frame.
The free cap would have two screws in it where the SMA wires would attach. Figure 36 shows
the CAD assembly of the bowing shim prototype. Dimensional schematics can be found in
Appendix A, Figure 58.
39 Macor is an ultra-high temperature glass-mica ceramic characterized by its good machinability.
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Figure 36: CAD assembly of bowing shim prototype.
Two wires would be used in this design. They would be activated alternately to allow one
wire to cool down while the other wire contracted. This would allow the device to cycle more
quickly.
4.2.2.2 Manufacturing and Assembly
The bowing shim prototype's frame and shim caps were manufactured on an SLA. The
Macor rods were purchased in the right diameter (1.6 mm) and were cut to the width of the
frame. They were then inserted into holes running through posts on each end of the frame. Two
200 tm diameter by 300 mm length SMA wires were held to the sliding end cap by pinching
their ends against the cap with the screws. The free ends of the wire were run off to the side of
the frame where a screw was placed to act as the grounding electrode. The wires were looped
back and forth five times and pinched against the frame with two 1.6 mm by 10 mm screws that
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also served as each wire's electrode. Figure 37a and Figure 37b show a top and isometric view of
the assembled bowing shim prototype.
a) b)
Figure 37: a) Top view of bowing shim prototype; b) Isometric view of bowing shim prototype.
4.2.2.3 Testing
The prototype was set up in a small vise for stability and a power supply was attached to
each of the SMA wires. The two 200 pm diameter by 300 mm length wires had a calculated
electrical resistance of 9.5 Q each. This required the power supplies to be set to 5.8 V to provide
the wires with a 610 mA operating current. 40 The power supplies were triggered manually in
sequence once the shim pushed the SMA wires back to their at-rest position. The shim did
successfully bow outwards by approximately 12 mm, as shown in Figure 38, but it quickly
became apparent that the bowed shim could not produce enough force to reset the SMA wire
quickly enough. This essentially negated the advantage of having two alternately actuating wires.
Furthermore, the power source used to activate the SMA wires was not ideal. A 610 mA constant
40 610 mA sustained operating current obtained from the manufacturer's published specifications for 200 pim
wire[27].
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operating current was recommended in the manufacturer's specifications but this actuated the
wires very slowly. A higher current could be used for shorts periods of time.
Figure 38: Bowing shim prototype actuating during testing.
4.2.2.4 Status
Although this first iteration of the bowing shim prototype had shortcomings, its
development continued with modifications, leading to version 1 of the SMA AMP device
discussed in the following section.
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4.3 SMA AMP Device Version 1
4.3.1 Design
The first full version of the SMA device used a mechanism that was essentially the same
as for the bowing shim prototype. Modifications to the original mechanical and electrical designs
resulted in improved performance and brought it closer to an implantable prototype.
4.3.1.1 Mechanical System Modifications
The most significant modification to the bowing shim design was to incorporate four
wires into the device. The published specifications for SMA wires recommended a 5.5-second
cool-down time for a 250 pm diameter wire[27]. If only two opposing wires were used, each
would be under electrical tension for approximately 100 ms and would rest for approximately
400 ms.41 In order to increase the length of the rest period for each wire, two additional wires
were added. These could be actuated in sequence to give each wire a 100 ms uptime with a 900
ms downtime. This 900 ms rest period was still not equal to the manufacturer's
recommendations but it was estimated that it would be long enough to allow the device to
function for brief periods of time. The addition of two more wires also doubled the number of
wire lengths crossing the top of the device. This meant that the pulley slots at each end of the
frame had to be doubled in number and each had to be narrowed in order to maintain a
reasonably compact form factor for the frame. Ceramic pulley wheels each 2 mm wide with a 1.6
mm rod running through them were designed to fit into each slot. Two new screw-electrodes also
had to be added to the frame's end. Finally, the frame itself was given a curved base to better fit
41 Time estimates based on a 2 Hz (120 bpm) pulse, the upper norm for a stable test animal.
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onto the epicardium of the LV. Figure 39 shows the CAD assembly design of the modified
frame. Dimensional schematics can be seen in Appendix A, Figure 59.
Figure 39: CAD assembly of SMA AMP device Version 1.
4.3.1.2 Electrical System Modifications
As noted during the testing phase of the bowing shim prototype, the contraction of the
SMA wires when using a DC power source was too slow to actuate the wires at the desired rate.
The updated design employed large electrolytic capacitors instead of DC power supplies. The
capacitors used were Mallory 33 mF, 75 V electrolytic capacitors. The charge capacity of these
capacitors was calculated based on the Joule heating required to bring a 350 mm long, 250 pm
diameter SMA wire to its transition temperature of 70'C. Equation (4) was used to calculate the
mechanical work performed by the SMA wire. Since SMA has an electrical to mechanical
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energy transfer efficiency of 3%, the number yielded by Equation (4) was divided by 0.03 to find
the electrical energy required to heat the wire[28].
(4) W:= FSMA-AL
It was calculated that 4.7 J would be needed to heat the wire to above its transition
temperature. Four 33 mF electrolytic capacitors were available from lab stores. Equation (5) was
used to calculate the voltage required to store the 4.7 J of energy in 33 mF capacitors.
E:= I C.V
(5) 2
It was calculated that the capacitors would need to be charged to 16.9 V in order for them
to store the required amount of energy (shown in Appendix D). This number was rounded up to
20 V to compensate for the fact that a capacitors discharge follows a negative exponential curve,
and the end of the discharge would be too slow to be effective. The discharge time would be
regulated manually.
4.3.2 Manufacturing and Assembly
The frame and shim end caps were manufactured on an SLA, then assembled with an 45
mm long by 12.7 mm wide by 150 tm thick piece of shim. Ceramic pulleys were machined 42
and inserted into each slot (16 in total) and a 1.6 mm stainless steel rod was inserted through
each set of 8 pulleys at each end of the frame. A 1.6 mm rod was inserted into the frame through
42 This process is discussed further in the next subsection.
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the static shim end cap. Four 350 mm long by 250 pm diameter wires were cut and screwed
down, two facing in each direction along the frame's length, into the sliding shim end cap with a
1.6 mm screw and washer. The wires were threaded five times across the length of the frame and
pinched between the screw head and a nut of an M1.6 by 20 mm long screw. Each screw was
entered through a 1.6 mm hole in the screw-electrode mounts on each corner of the frame. A nut
was placed on the opposite side of the mount to allow the tension on the wire to be adjusted. Two
120 V, 0.25 A power supplies were each connected to two 33 mF capacitors. High-current rated
toggle switches were placed after each capacitor and the toggles' outputs were each connected to
one of the SMA wires' electrodes. This allowed each wire to be toggled on and off manually.
Figure 40 shows a photo of the device assembly.
Figure 40: Final assembly of SMA AMP device Version 1.
74
4.3.2.1 Ceramic Pulley Machining
Machining small components from ceramic is inherently difficult even when dealing with
machinable ceramics such as Macor since it easily chips or breaks. Proper execution of the SMA
AMP device required 5 mm diameter pulley wheels machined from ceramic that would allow
SMA wires looped around the ends of the base frame to roll smoothly and not hinder the
device's actuation while at the same time electrically isolating the wires from one another. The
CAD design of these pulley wheels is shown in Figure 41 while the dimensional schematics can
be seen in Appendix A, Figure 60.
Figure 41: CAD of Macor pulley wheel.
The pulley design is quite simple but the wheels' scale made their production using only
a CNC lathe problematic. The stock used for the wheels was a 6.35 mm rod of glass-mica
machinable Macor. The profile of the wheel could be turned fairly easily using a very low
material removal rate but the wheels could not be cut off without breaking the rod where the
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collet of the lathe held the stock. A two-part process was developed where the profile was turned
on a Mazak CNC lathe and the wheel was separated from the stock on a HAAS 3-axis CNC mill
using a custom-built cutoff jig. A buffing grinder was then used to finish the sides of the wheels.
The cutoff jig needed for the 3-axis mill enabled the mill to perform a precise cut at a reasonably
high throughput rate. The jig was machined from a 50 mm by 50 mm by 20 mm thick block of
aluminum. A 2 mm high step was machined out of one of its sides and two holes were drilled
near the edge of the step where a carbide grit saw blade was bolted. Figure 42 shows the
assembled cutoffjig.
50mm
Figure 42: Ceramic pulley wheel machining cutoff jig.
Once assembled, the jig was secured in a vise and the Macor rod with the turned wheel
profile was inserted into a drill chuck in the mill's spindle. The wheel was touched down against
the step's bottom, then the rod was slowly fed against the carbide grit blade. Only a small
76
I
amount of finishing work was required to deburr the wheel's inner edge and to adjust the
thickness of the wheel down to 2 mm. 43 Figure 43a and b Figure 43show a finished wheel.
a) b)
Figure 43: Ceramic pulley wheel, finished product: a) Frontal view; b) Side view.
4.3.3 Testing and Analysis
Tests were performed on this shim bowing device to see if the mechanism functioned as
effectively as desired. First, a test of the device's outward displacement of the shim was
measured. A power supply was connected to a 33 mF electrolytic capacitor that was in turn
connected to a toggle switch. The toggle switch's output was connected to one of the device's
protrusion wires. 44 The power supply was set to 20 V and the capacitor allowed to charge for at
43 Since the carbide grit blade was not perfectly straight, there were some variations in wheel thicknesses after the
cutoff step.
44 For ease of reference, the wires that bow the shim are referred to as protrusion wires while the wires that return
the shim to its original flat position are referred to as resetting wires.
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least 10 seconds. Once the capacitor reached its set voltage the toggle switch was triggered and
the wire bowed the shim to a bulge that extended 13 mm out from the frame.45 The force output
of the device was also measured. With the same electrical connections in place, the device was
placed in a clamp with the shim in the vertical plane when at rest. An Extech Instruments 475040
force transducer was placed beside the device with the transducer's probe 5 mm away from the
frame's edge. The toggle was triggered for approximately 1 second and the force on the
transducer's gauge was recorded. This procedure was repeated three times then the transducer
was moved 3 mm away from the frame's edge. This did not have a significant effect on the
result. Table 6 shows the results obtained from the series of tests.
ATTEMPT FORCE (N) AREA (M2) PRESSURE (KPA)
1 13.42 2.65E-04 50.66
2 14.14 2.65E-04 53.38
3* 15.14 2.65E-04 57.15
*Measurement taken at 3 mm from base.
Table 6: Force measurement results from tests to SMA AMP device Version 1.
The area in Table 6 was calculated from the dimensions of the probe used at the tip of the
force transducer. A probe approximating the profile of the simulation apparatus' balloon was
manufactured on an SLA. This was done to better compare the pressure output of the SMA
device with the data obtained from the simulation experiments. As can be seen, the pressure
output of the device surpasses by far the 11 kPa minimum determined from the experiments.
Once these tests were performed, all of the wires were connected to their power sources.
The wires were manually actuated in sequence every second. This form of actuation is decidedly
45 Measured by placing a ruler on the frame beside the shim bulge.
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imprecise but accomplished the main goal, which was to see if this method of actuation was
feasible or if the opposing wires would place too much stress on the wire connections.
4.3.4 Status
The mechanism was tested and performed well enough to warrant further development.
Certain shortcomings such as the wire connections would have to be improved before a
successor to this design could be taken to an in-vivo test. It should also be tested on the in-vitro
model described earlier but the frame first had to be redesigned to include loops that can be used
to suture the device to the LV ellipse's surface and ultimately to an in-vivo animal's epicardium.
4.4 SMA AMP Device Version 2
4.4.1 Design
SMA AMP Version 1 served to test the function and feasibility of the shim bowing
mechanism for potential use in an implantable device. Version 2 of this AMP device functioned
in the same fashion as Version 1 but its packaging and electronics were built according to the
specifications required for in-vivo testing.
4.4.1.1 Mechanical System Modifications
In the second iteration of this device, the shim bowing mechanism remained identical to
the one in Version 1. Changes were made to compact the device's frame as much as possible to
enable it to properly fit inside of a sheep's pericardial space. Version 1's frame was relatively
quite thick. This was purposely done after discovering in an early version of the original bowing
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shim prototype that the entire frame would flex under the strain of the SMA wires. In order to
avoid this problem in Version 2, a 1.6 mm diameter cylinder was removed from the length of the
frame and replaced with a stainless steel rod to increase the frame's stiffness. The frame's width
was reduced by thinning the separators between each Macor pulley and also thinning the
electrode posts at each corner of the device. Overall, the frame's dimensions were reduced from
70 mm long by 35 mm wide by 19 mm thick for Version 1 to 65 mm long by 27.3 mm wide by
14 mm thick for Version 2. Suturing loops also had to be added to the frame's exterior to allow
the device to be fixed to the in-vitro testing apparatus and eventually to a sheep's heart. A cutout
was also made at one end of the frame where a five pin plastic male plug-in could be inserted.
Finally, a removable top had to be built to insulate the SMA wires from potentially touching any
tissue during an in-vivo study. Snap-in grooves were designed into the frame's sides and the
male equivalent was built into the top's inner sides. Figure 44 shows the CAD assembly design
of the modified frame. Dimensional schematics can be seen in Appendix A, Figure 61.
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Figure 44: CAD assembly of the SMA AMP device Version 2.
4.4.1.2 Electrical System Modifications
The power source used for Version 2 was essentially the same as that of Version 1 save
one new element. Two DC power supplies were again used to charge four 33 mF electrolytic
capacitors. The new element was a power-triggering circuit based around four Insulated Gate
Bipolar Transistors (IGBT). IGBTs are a particular variety of bipolar transistors that are capable
of switching very high voltages and currents with a relatively small gate (input) voltage (15V).
One IGBT was used for each SMA wire. Each IGBT collector was connected to one of the 33
mF electrolytic capacitors while their emitters would be connected to the SMA AMP Version 2
device. A non-inverting amp of Gain 3 was placed between the outputs and the gates of each
IGBT so that the gate input would only need to be a standard 5 V digital signal. In this
configuration, a square wave generator could be connected to two IGBTs leading to the device's
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protrusion wires with its complementary output connected to the other IGBTs leading to the
device's resetting wires. This provided a frequency adjustable triggering signal that would be the





















4.4.2 Manufacturing and Assembly
The frame and removable top were both manufactured on an SLA. Once completed, the
40 mm long by 12.7 mm wide by 150 ptm thick piece of shim, the Macor pulleys, stainless steel
rods and screw electrodes were set into place. Electrical connections needed to be run from the
screw electrodes to the 5-pin connector. The two electrodes on the opposite side of the connector
were attached to the stainless steel rod running the length of the frame. The other end of the rod
was then connected to the appropriate pins on the 5-pin connector. Four 325 mm long by 250 pm
diameter SMA wires were threaded from the static shim end cap, through the pulleys, then
attached to their respective electrodes. Figure 46 shows the final assembly of the device.
Figure 46: Final assembly of SMA AMP device Version 2.
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The power-triggering circuit was designed in the Allegro software program and built out
of a double-sided copper prototyping board. It was then populated with the IGBTs, op-amps and
other components and female banana plugs were installed at the circuit's inputs and outputs.
Figure 47: Power triggering circuit.
4.4.3 Testing and Analysis
Testing of the SMA AMP Version 2 device was performed on the in-vitro instrument.
Since the mechanism design was the same as for SMA AMP Version 1, force measurements
were not repeated. Instead the in-vitro instrument was used to test the device's depth of
protrusion when placed against a load. The device was sutured onto the LV ellipse using sewing
buttons as a backing support. The device was then connected to the capacitor-toggle box setup
used earlier for SMA AMP Version 1 tests. The capacitors were charged to 20 V, the toggle was
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tripped and the protrusion's depth was measured with a ruler held beside the frame. The device's
protrusion depth was approximately 10 mm. This slightly shallower protrusion was most likely
due to the extra resistance caused by the close proximity of the suture points. This device also
used slightly shorter wires than the SMA AMP Version 1 (325 mm versus 350 mm) giving it a
slightly shorter contraction length. Sequential contraction was then attempted using the toggle
box's switches, however the screw that attaches the wires to the shim's sliding end cap remains
problematic. After only a few contractions, two of the wires separated from the screw, rendering
the device inoperative.
Figure 48: SMA AMP Version 2 device sutured to in vitro ellipse.
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4.5 Future Research
Future development of this SMA device will continue. The current iteration of SMA
AMP device has proven effective at creating the displacements required to treat MR through LV
remodeling but will require certain improvements before it is reliable enough to use during an in-
vivo procedure. Further research also needs to be directed towards making this device truly gated
to the heart's cycle. A VB interface should be created to do this. A future iteration of the SMA
AMP will be tested in-vivo as soon as an effective solution to the gating problem has been found
and the device performs reliably enough to warrant an in vivo experiment.
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5 Conclusions and Future Research
The previous chapters present advances in the design and development of a new approach
to the treatment of ischemic mitral regurgitation. The concept of using an artificial muscle patch
to treat MR has been proofed. The AMP simulation device showed in vivo that an active patch
device can relieve MR by displacing the papillary muscles of the left ventricle by approximately
12 mm.
Device performance data also provided useful specifications for ongoing development of
this approach. Calculations indicated that the simulation device needed to exert at least 11 kPa of
pressure against the LV wall in order to displace it. Information on the timing of the AMP
simulator's activation was then used to develop design criteria for a shape memory alloy AMP
device as described in Chapter 4.
Two SMA AMP devices were built and tested. The first was a non-implantable version
used to test the design's force output. A maximum force output of 15.14 N was achieved,
yielding an equivalent of 57.15 kPa for the test probe used. The second iteration was designed as
an implantable version with all suturing loops, electrical connections and device coverings
required for use in an in-vivo study. This second device was tested with the in-vitro instrument
(the development of which is described in Chapter 3).
A number of design and manufacturing challenges were overcome in this research which
provide lessons for further work on artificial muscle technologies. Many different mechanisms
for displacement magnification needed to be tested in order to achieve the 12 mm displacement
required to affect MR. This was made more difficult by the need to keep the device small enough
to fit within a sheep's pericardial space without affecting its normal heart function. Development
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of an SMA device that could be implanted into a living animal also proved to be challenging.
Special attention needed to be paid to the device's electrical connections and to the SMA wires
to ensure that they could not touch any tissue within the chest cavity.
From a manufacturing perspective, many machining challenges were overcome. The
most prominent of these was the machining of small Macor parts. A novel strategy was
developed to enable the production of a large number of Macor pulleys with the existing
equipment (CNC lathe, 3-axis CNC mill). Since small detailed Macor parts are invaluable in
creating SMA assemblies and devices, this style of manufacturing will undoubtedly find future
uses.
Future work will be directed to the further development of the SMA AMP device. Once
an advanced prototype has been completed, in-vivo testing will be undertaken. Looking beyond
SMA technology, conducting polymer actuators will be the next step for active patch
development. Conducting polymer actuators have the advantage of being a very low-power
consumption technology. This would enable the creation of a much more compact implantable
device that can eventually be considered for clinical use. More development will also be done on
the in-vitro testing instrument. A more comprehensive instrument incorporating a variety of
sensors will be built to test future AMP prototypes.
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Appendix A: Dimensional Schematics












Figure 49: Schematic of Base Ring Version 1.
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Figure 52: Schematic of syringe-actuator coupler.
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Figure 56: Schematic of in vitro assembly frame.
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Dynamic Viscosity of Fluid







v = 8.9 x 10- 7 M
S
Gravitational Acceleration
Pressure Drop Across Individual Sections of System
Equations derived from the Navier-Stokes equation of motion
Section 1: Syringe
R1 :=20- 10 -3 -ir












LI := 0.1. iT
A 1 = 1.257x 1- 3 2
Mean velocity
Maximum velocity for a parabolic distribution
See lab book NS1 p.10
Time required to reach Vmax
(Based on model of 1/3t accelerating,
1/3t cst Vmax, 1/3t decelerating
Acceleration of Fluid in Section 1






8 . p - al- pAPI := 8 I+ al - p - L
7c - RI 4
AP1 = 1.084x 10 Pa
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2
Section 2: Connecting Tube
R 2 := 3.25 -10 3rr









8 - - Q - L2
AP2 := 7r-R
A 2 = 3.318x 10 5 M2
Mean velocity
Maximum velocity for a parabolic distribution
See lab book NS1 p.10
Time required to reach Vmax
(Based on model of 1/3t accelerating,
1/3t cst Vmax, 1/3t decelerating
Acceleration of Fluid in Section 2





4AP2 =3.334x 10 Pa
Section 3: Patch
W3 := 0.03rr H3 := 0.06rr L3 := 5.56 -310 3
L2:= 1 -n-










A 3 = 1.8 x 10- 
3 M2
Mean velocity
Maximum velocity for a parabolic distribution
See lab book NS1 p.10
Time required to reach Vmax
(Based on model of 1/3t accelerating,
1/3t cst Vmax, 1/3t decelerating










Pressure Variations Due to Head Loss
Result of viscous energy dissipation
Head loss due to friction in section 2 (Sections 1 & 3 negligible)
Darcy Friction Factor for Plastic Pipe
(From Moody diagram)
21
Ahf:= f - V2avg
APhf :=Ahf - p - g
L2
(2 - R2)
Head loss due to friction Ahf = 0.136m
APhf = 1.329x 10 Pa Pressure variation due to friction
Head loss due to abrupt interfaces (1 -> 2 and 2 -> 3)
Interface 1 -> 2
Kc:= 0.4. ( I
A2)
A I
Contraction Coefficient KC = 0.389
Ahl 2 := KC V2avg 
APh12 := Ah12 - p g
Interface 2 -> 3
A22
Ke := (1 A)
A3
Ah 23 := Ke - 2ag
APh23 := Ah2 3 - p g
Head loss due to contraction
Pressure variation due to contraction
Expansion Coefficient
Head loss due to expansion
Pressure variation due to expansion
Ah 12 = 0.029m
APh12 = 280.395Pa
Ke = 0.963




Total Pressure Drop Across System
APtotal AP1 + AP 2 + AP3 + APhf + APh12 + APh23
APtotal 3.673 x 104 Pa
Required Applied Force
Estimated maximum pressure
applied to the patch face
APhf
P2 .5  PA + AP 3 + APh23 + 22
P2.5 = 5.136x 104 Pa
P1  PA + APtotal
Pi 8.673x 10 Pa
FLM P1 - Al
FLM = 108.993N
Pressure halfway down the connecting tube
(Potential site of pressure gauge)
Pressure at the Syringe's plunger
Force required from the Linear Motor in order
to produce the desired force against the myocardium
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3A:=50 - 10 Pa
Appendix C: Calculations for SMA Lever Prototype
SMA Lever Design
SMA-50mm




Angled Arm Length and Angle Calculation
01= Starting angle of arm
02= Change in angle after SMA contraction




x2  = O Icos0 1
xi = r 
- x2
y = xI-cos0 1
cos(O 1 + 02) = yr
02= acos - 6O1
Summarized equation for displacement angle
02= acos cosi - dsMt --01
For fixed arm length
r:= 5mn
dSMA: 2.On
2(01):= acos (cos( -0 1) SMA
0 2(01):= acos (cos(
-0 180
01)d SMA -0 1
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01 : 0, 0.1.. 2
Depression Arm Rotation as a Function of Initial Angle
I I I I I
40
30
0 0.2 0.4 0.6 0.8
01






Length of depression arm
1:= 2010- 3r
Surface area of depression arm
Aa:= 2 0 -10 3.10.10 m 2
Fa:= P-A a







For simplicity, Fa will be taken at the equilibrium point of the depression arm
(at its center)
Fn OA F MA
""^Fe''^ SM






Fn is the force on the angle arm normal to its angular motion
FSMA is the resulting force required by the SMA in order to achieve the
desired displacement
From the Torque balance equation
Fa*- = Fn-I
2





From the angle calculations above, we see that 02 varies between 30 and 60 degrees
OSMA is taken as the angle after the SMA contraction since it is at this moment that maximum
































































AL:= L-4% AL = 0.014m
D:= 254-10- 6
A := 7r- D 2 A = 5.067x 10 8 2
Force output of SMA Wire:
SMA Wire Presure Output P:= 200 10 Pa
FSMA := P-A FSMA = 10.134N
Work Performed by SMA Wire:
W := FSMAAL W = 0.142J
Electrical to Mechanical Work Efficiency = 3%
Therefore the energy
required to actuate the wire
w
E 0:= E = 4.729J
Energy of a Capacitor:
E:= 2C-V
2
For C:=3310 3 F
VCAP:= .- VCAP:= 16.9\
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